← Research library

AED bone/cartilage composition and reported knee-osteoarthritis comparison — RU2299741C1

Patent disclosure · 2007

What the patent describes
29 knee-osteoarthritis patients ages 52–72; the patent states random allocation and describes 12 saline controls. Treatment subgroups differed by age, disease severity and dose.
Reported evidence
The patent reports pain reduction and better mobility in 54.5–62.7% of cases across severity subgroups after 20 days of intramuscular AED, without substantial radiographic change. Control response and subgroup counts are not supplied. It also contains separate animal and cartilage-explant examples.

Reported patent results

Reported findings

The patent reports less pain and better knee mobility after 20 days of intramuscular AED. It reports no substantial X-ray change.

29 knee-osteoarthritis patients ages 52–72; the patent states random allocation and describes 12 saline controls. Treatment subgroups differed by age, disease severity and dose.

Results · Original patent, clinical example 5
MeasureResultComparison, timing and statistics
Pain and joint mobilityImprovement reported in 54.5–62.7% of casesRange across disease-severity subgroups; subgroup counts and control response are not reported · 20-day course
X-ray findingsNo substantial radiographic changeDuring the reported treatment period
Patient population29 patients ages 52–72; 12 saline controls describedDisease duration 5–20 years
Age 52–60, initial disease1 microgram intramuscularly once daily20 days
Age 60–65, moderate deformity10 micrograms intramuscularly once daily20 days
Over 65, most marked deformity5 mg intramuscularly once dailySource units retained; severity-dependent groups are not a dose-response trial · 20 days

These are patent-reported human observations, not a peer-reviewed clinical trial. The percentages describe reported symptom responses, not the amount of cartilage restored or a treatment-versus-control effect.

Source for these results ↗ · Reviewed 2026-10-31

Patent claims and provenance

Molecule. The claim explicitly identifies Ala-Glu-Asp (AED), with bone/cartilage applications; this is not the cartilage-derived PCC mixture.

A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.

Publication
RU2299741C1 ↗ · 2007-05-27
Earliest priority / filing
2006-05-30 / 2006-05-30
Original applicant / assignee
Общество С Ограниченной Ответственностью "Сиа Пептайдс"
Indexed status
Not shown; official status unverified · checked 2026-11-06
Patent family
38310627 · family publications are related filings, not independent studies.
Original title, inventors and related publications

Peptide normalizing metabolism in osseous and cartilage tissue, pharmaceutical composition based on thereof and method for its using

Inventors: Владимир Хацкелевич Хавинсон (RU); Владимир Хацкелевич Хавинсон; Евгений Иосифович Григорьев (RU); Евгений Иосифович Григорьев; Владимир Викторович Малинин (RU); Владимир Викторович Малинин; Галина Анатольевна Рыжак (RU); Галина Анатольевна Рыжак.

RU2299741C1 · EA010574B1 · WO2007139433A1

Original patent PDF ↗

Patent collection and status interpretation →

Study limitations and source details

Study limitations

  • Patent-reported comparison, not a recovered peer-reviewed clinical trial.
  • Allocation methods, masking, subgroup denominators and independent replication remain unresolved.
  • This AED example is not the PCC Phase II program reported in 2023.

Source details

Original patent text and translated examples checked; filed 2006, published 2007. Clinical example 5 rechecked on 31 October 2026, including doses, symptom-response range and absent radiographic change.

Selected reported results and source limitations reviewed; not a complete risk-of-bias or experimental audit.

Sources checked

Citation

Patent / reported experimentsFull text available

V. Kh. Khavinson, E. I. Grigoriev, V. V. Malinin, G. A. Ryzhak. AED bone/cartilage composition and reported knee-osteoarthritis comparison — RU2299741C1 Russian patent RU2299741C1; related Eurasian patent EA010574

Study source ↗ · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards